Lupin shares trade 3% higher on tentative USFDA approvals
On November 23, Lupin announced receiving the USFDA's tentative approval for its Abbreviated New Drug Application (ANDA) for Canagliflozin Tablets to market a generic equivalent of Invokana Tablets of Janssen Pharmaceuticals, Inc at its Pithampur facility.
• Lupin received tentative approval from the USFDA for its Abbreviated New Drug Application for Canagliflozin Tablets, a generic equivalent of Invokana Tablets.
• The company also received approval for its ANDA concerning Bromfenac Ophthalmic Solution, mak......read more
F&O stocks to buy today: Tata Steel, Ashok Leyland among top 9 trading ideas for 22 November
Positive setup was seen in Oberoi Realty, MFSL, Ashok Leyland, SBI Life, Aurobindo Pharma, Astral, HDFC Life, Alkem, Lupin, JSW Steel, Titan, RIL, Exide Industries, etc. among others.
The Economic Times
• The Indian market is expected to trade higher on Wednesday, with positive setup seen in stocks like Oberoi Realty, MFSL, Ashok Leyland, SBI Life, Aurobindo Pharma, Astral, HDFC Life, Alkem, Lupin, JSW Steel, Titan, RIL, and Exide Industries.
Why Voda Idea, Tata Power are Sanjiv Bhasin 2 top bets from this Diwali to next
“In pharma, it is better to buy a basket now than individually because select stocks have been outperformers and you want to participate in the whole basket. As a disclosure, Lupin and Aurobindo are two which we have accumulated. We still think that there is upside in both those stocks.”
The Economic Times
• Sanjiv Bhasin, Director at IIFL Securities, recommends buying a basket of pharma stocks rather than individual stocks.
• He also suggests investing in two midcap mutual funds with a pharma thematic scheme.
• Bhasin's top Diwali stock ideas are Idea and T......read more
Lupin hit 52-week high as investors cheer stellar Q2 earnings
The strong performance in the US market, aided by the launch of blockbuster respiratory drug Spiriva was the major growth driver for Lupin in Q2
• Lupin reported a stellar set of earnings for the July-September quarter, with a surge in net profit and strong revenue growth driven by the launch of blockbuster respiratory drug Spiriva in the US market.
• The company's operational performance also impr......read more
Netflix is still growing its subscriber base – here's how a local approach is helping
According to its latest letter to shareholders, it added 8.8 million new subscribers in the third quarter of 2023, on top of the 5.9 million it gained in the three months before that. The total number of subscribers worldwide is now 247.2 million.
The Economic Times
• Netflix has successfully rebounded from a tough year in 2022, adding 8.8 million new subscribers in the third quarter of 2023 and gaining a total of 247.2 million worldwide.
• The company's success can be attributed to its crackdown on password sharing a......read more
After losing the wealth-creation plot somewhat, the wheel of fortune is once again turning the GenNext Marwari way. Higher- quality education, exposure to global management techniques and better corporate governance have rekindled a new hunger for success among GNMs - GenNext Marwaris. A fresh upsurgence is on the way.
Lupin gets USFDA nod to market generic antifungal tablets
The approval granted by the US Food and Drug Administration (USFDA) for the abbreviated new drug application of Fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg, Lupin said in a regulatory filing.
The recent Supreme Court ruling against same-sex marriages in India will not hinder the progress of inclusion in Corporate India, according to HR and diversity heads at leading companies. They believe that companies will continue to strive for inclusivity, as they have recognized the benefits it brings in terms of innovation and profitability. While a clearer verdict on marriage equality would have been helpful, companies are already taking steps to support LGBTQIA+ rights through various initiatives such as insurance coverage for partners, gender-neutral facilities, and ally programs.
Indian drug maker Lupin has received tentative approval from the US Food and Drug Administration (FDA) to market a generic medication used to reduce excessive daytime sleepiness. Lupin plans to produce the medication at its facility in Somerset, US.
India Inc keeping a close watch on conflict, employee safety in Israel
In a statement, IT industry body Nasscom said: “We condemn the horrific act of terrorism on Israel that has led to loss of innocent lives and precipitated the conflict. The technology industry in India, we value our partnership with Israel as an innovation hub and will continue to strengthen our engagements.” As regards the current crisis, the industry has a limited presence in Israel largely focused on innovation partnerships and R&D.
Pharma cos can supply generic Bedaquilineto other countries
Multinational pharmaceutical company Johnson & Johnson (J&J) has announced that it will not enforce secondary patents for its anti-TB drug Bedaquiline in low and middle income countries. This means that Indian pharmaceutical companies will be able to supply generic versions of the drug without the fear of litigation.
Lupin inks pact to acquire 5 drug brands from Menarini for Rs 101 crore
Lupin said it has inked a pact to acquire five drug brands from Italian firm Menarini for Rs 101 crore. The company has signed an agreement to acquire five legacy brands catering to gastroenterology, urology and anti-infective segments, the Mumbai-based company said in a statement.
There is no risk to rally in smallcaps and broadcaps for now: Bino Pathiparampil, Elara Securities
“We believe that flows will go more into relatively lower-valued stocks within the midcap and smallcap indices on a growth-adjusted basis. We have identified the cheapest stocks on a PEG basis and from among them, we have identified the cheapest stocks on a PEG basis and from among them, we have identified a few lists of stocks, which potentially look pretty attractive.”
J&J, Lupin cut prices for tuberculosis drug in lower-income countries
Johnson & Johnson and Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, according to the Stop TB Partnership. The new prices, $130 for J&J and $194 for Lupin for a six-month course of treatment, represent a 55% and 33% reduction, respectively. Bedaquiline is a key part of recommended treatment regimens for drug-resistant TB infections, and this price reduction will help broaden access to the life-saving drug.
Lupin gets USFDA nod to market generic drug for treatment of lung disease
Lupin on Friday said it has received approval from US FDA to market a generic product, used in the treatment of a lung disease, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market Pirfenidone tablets in strengths of 267 mg and 801 mg, the Mumbai-based drug maker said in a statement.
3 stocks to buy in pharma; PFC and REC good proxies for power: Rahul Shah
“The entire power sector is going to get rerated and there could be a lot of room for them, especially PFC and REC. If somebody wants to play a proxy to power, then these are the companies with a limited downside and there could be a good upside from here also.”
Lupin acquires two diabetes brands from Boehringer Ingelheim
Lupin has been marketing Ondero and Ondero Met since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelheim and the Indian pharma company acquired the two diabetes brands for Rs 235 crore.